Home
GLUE
GLUE News

Latest Monte Rosa Therapeutics Inc. (GLUE) News on April 2, 2025

Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect

GuruFocus.com

12 days ago

Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect

Mixed data results for two Monte Rosa molecular glue degraders

Clinical Trials Arena

12 days ago

Mixed data results for two Monte Rosa molecular glue degraders

MT Newswires

12 days ago

Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $17 From $15, Maintains Outperform Rating

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

Zacks

13 days ago

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

MT Newswires

13 days ago

Monte Rosa Therapeutics Files $400 Million Mixed Shelf

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

GlobeNewswire

13 days ago

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

GlobeNewswire

22 days ago

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

3 Top Cancer Biotechs to Keep An Eye On in 2025

Zacks

a month ago

3 Top Cancer Biotechs to Keep An Eye On in 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

a month ago

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

2 months ago

Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans

Monte Rosa Therapeutics provide corporate update, key milestones 2025

TipRanks

3 months ago

Monte Rosa Therapeutics provide corporate update, key milestones 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

GlobeNewswire

3 months ago

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

3 months ago

Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

MT Newswires

4 months ago

Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression

MT Newswires

4 months ago

Monte Rosa Closes Global License Agreement With Novartis

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study

TipRanks

4 months ago

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?

Zacks

4 months ago

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire

4 months ago

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire

5 months ago

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),

Simply Wall St.

5 months ago

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Monte Rosa Therapeutics: Q3 Earnings Snapshot

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice

Zacks

5 months ago

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade

Zacks

5 months ago

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

TipRanks

5 months ago

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis

GuruFocus.com

5 months ago

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

Investor's Business Daily

5 months ago

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

MT Newswires

5 months ago

Top Midday Gainers

This Biotech Stock Has Doubled Its Value Today—Here's Why

Investopedia

5 months ago

This Biotech Stock Has Doubled Its Value Today—Here's Why

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis

Investor's Business Daily

5 months ago

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis

MT Newswires

5 months ago

Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $15 From $11, Maintains Outperform Rating

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Reuters

5 months ago

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Why Is Monte Rosa Therapeutics Stock Surging On Monday?

Benzinga

5 months ago

Why Is Monte Rosa Therapeutics Stock Surging On Monday?

MT Newswires

5 months ago

Monte Rosa Therapeutics Enters Global License Deal With Novartis; Shares Jump Pre-Bell

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

BioPharma Dive

5 months ago

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire

5 months ago

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

GlobeNewswire

5 months ago

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 09/25/2024

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

7 months ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Simply Wall St.

7 months ago

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

MT Newswires

7 months ago

Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

GlobeNewswire

7 months ago

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

8 months ago

Monte Rosa Therapeutics: Q2 Earnings Snapshot

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

8 months ago

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

GlobeNewswire

9 months ago

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

GlobeNewswire

9 months ago

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

GlobeNewswire

10 months ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

10 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

10 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

10 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

10 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

10 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

10 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

10 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

10 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Simply Wall St.

10 months ago

Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

MT Newswires

10 months ago

Monte Rosa Therapeutics Names Three Insiders to Leadership Team

Monte Rosa Therapeutics Announces Leadership Team Promotions

GlobeNewswire

10 months ago

Monte Rosa Therapeutics Announces Leadership Team Promotions

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

10 months ago

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

GlobeNewswire

10 months ago

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

MT Newswires

a year ago

Monte Rosa Therapeutics Prices $100 Million Public Offering

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GuruFocus.com

a year ago

Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Associated Press Finance

a year ago

Monte Rosa Therapeutics: Q1 Earnings Snapshot

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

MT Newswires

a year ago

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why

Zacks

a year ago

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Zacks

a year ago

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

a year ago

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

Zacks

a year ago

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

GuruFocus.com

a year ago

Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

Simply Wall St.

a year ago

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

Associated Press Finance

a year ago

Monte Rosa Therapeutics: Q4 Earnings Snapshot

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

GlobeNewswire

a year ago

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Unitil Increases Common Stock Dividend

GlobeNewswire

a year ago

Unitil Increases Common Stock Dividend

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Zacks

a year ago

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Sierra Bancorp (BSRR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a year ago

Sierra Bancorp (BSRR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Despite Fast-paced Momentum, Carrols Restaurant (TAST) Is Still a Bargain Stock

Zacks

a year ago

Despite Fast-paced Momentum, Carrols Restaurant (TAST) Is Still a Bargain Stock

Southside Bancshares, Inc. (NASDAQ:SBSI) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Southside Bancshares, Inc. (NASDAQ:SBSI) Q4 2023 Earnings Call Transcript

Oppenheimer Holdings Full Year 2023 Earnings: EPS: US$2.81 (vs US$2.77 in FY 2022)

Simply Wall St.

a year ago

Oppenheimer Holdings Full Year 2023 Earnings: EPS: US$2.81 (vs US$2.77 in FY 2022)

West Bancorporation Full Year 2023 Earnings: EPS Misses Expectations

Simply Wall St.

a year ago

West Bancorporation Full Year 2023 Earnings: EPS Misses Expectations

Compared to Estimates, Midland States Bancorp (MSBI) Q4 Earnings: A Look at Key Metrics

Zacks

a year ago

Compared to Estimates, Midland States Bancorp (MSBI) Q4 Earnings: A Look at Key Metrics

Midland States Bancorp (MSBI) Q4 Earnings and Revenues Beat Estimates

Zacks

a year ago

Midland States Bancorp (MSBI) Q4 Earnings and Revenues Beat Estimates

Midland States Bancorp Inc (MSBI) Reports Mixed Q4 Earnings Amid Economic Headwinds

GuruFocus.com

a year ago

Midland States Bancorp Inc (MSBI) Reports Mixed Q4 Earnings Amid Economic Headwinds

First Bank Announces Fourth Quarter 2023 Net Income of $8.4 Million and Full Year Net Income of $20.9 Million

GlobeNewswire

a year ago

First Bank Announces Fourth Quarter 2023 Net Income of $8.4 Million and Full Year Net Income of $20.9 Million

Eaton achieves Mansfield Rule certification: Legal Department Edition 3.0

Business Wire

a year ago

Eaton achieves Mansfield Rule certification: Legal Department Edition 3.0

Associated Press Finance

a year ago

Bar Harbor: Q4 Earnings Snapshot

Bar Harbor Bankshares Reports Fourth Quarter 2023 Results

ACCESSWIRE

a year ago

Bar Harbor Bankshares Reports Fourth Quarter 2023 Results

Share on Social Networks: